Intensification of metallo-enzyme production to unlock sustainable biocatalytic hydrogenation

**HydRegen**是牛津大学化学系于2021年衍生出来的。**我们的愿景：**HydRegen技术提供了更清洁、更安全、更快、更便宜的化学品制造。对生物和化学的深入了解使HydRegen团队能够从生物中选择最佳成分，并利用它们开发强大的生物技术，以解决化工行业的实际问题。我们预计我们的技术将在英国化工行业发挥作用，实现雄心勃勃的净零排放目标(到2050年)，并越来越多地采用工业生物催化和连续流程等使能技术。目前，我们正在应对药品和特种化学品(如香料和香料)制造中的挑战，并探索我们的技术扩大规模的潜力。价值较低的化学产品。**莫拉博士的团队(诺丁汉大学)**在能够循环H2和H+的新型氢酶方面拥有专业知识。HydRegen对这些酶很感兴趣，因为它们在“生产简易性”和“操作简易性”方面具有不同寻常的平衡。Morra博士的团队在酶生产方面拥有技术诀窍和设备，从早期的学术研究到生物反应器中可扩展酶生产的评估(高达100L)。**项目重点：**在这里，我们通过强化和扩大酶生产，并将产生的酶应用于奎努利诺生产的示范过程，解决HydRegen技术的制造准备方面的挑战。Quinuclidinol是一种重要的化学成分，存在于许多活性药物中。Morra博士和HydRegen博士于2022年通过BBSRC-NIBB资助开始了他们的合作。该项目允许双方实现这一合作的潜力。**项目产出：*降低对HydRegen至关重要的三种酶的生产成本。*将这些酶用于生产10克规模的化学积木Quninuclidinol。*验证Quuclidinol制造的成本和可持续性指标。*新的IP(酶生产、生物催化剂配方、过程化学)。*Quuclidinol基于生物的生产路线，满足英国生产的需要(成本、足迹、生产率、安全性、可持续性)。

**HydRegen** is a 2021 spin-out from the University of Oxford's Department of Chemistry.**Our vision:** The HydRegen technologies offer the potential for cleaner, safer, faster and cheaper chemical manufacture.Deep understanding of biology and chemistry allow the HydRegen team to select the best components from biology and use them to develop robust biotechnologies that solve real problems in the chemicals sectors.We expect our technologies to play a part in the UK chemicals sector meeting ambitious Net Zero emissions targets (by 2050) and increasing adoption of enabling technologies such as Industrial Biocatalysis and continuous flow process.Currently we are addressing challenges in the manufacture of pharmaceuticals and speciality chemicals (e.g. flavours and fragrances) and exploring the potential of our technologies for larger-scale, lower-value chemical production.**Dr Morra's Group (University of Nottingham)** have expertise in novel hydrogenase enzymes that are able to cycle H2 and H+. Theses enzymes are of interest to HydRegen due to their unusual balance in 'ease of production' and 'ease of handling'. Dr Morra's team have know-how and facilities in enzyme production spanning early-stage academic research through to evaluation of scalable enzyme production in bioreactors (up to 100L).**Project focus:** here we tackle challenges in manufacturing readiness of the HydRegen technologies by intensifying and scaling enzyme production, and applying the enzyme generated to a demonstrator process for quinuclidinol production. Quinuclidinol is an important chemical building-block present in a number of active pharmaceuticals.Dr Morra and HydRegen started their collaboration in 2022 via BBSRC-NIBB funding. This project allows both partners to realise the potential of this collaboration.**Project outputs:*** Lower cost-of-production of three enzymes that are critical to HydRegen.* Use of these enzymes for production of chemical building-block quninuclidinol at \>10g scale.* Validation of the cost and sustainability metrics for quinuclidinol manufacture.* New IP (enzyme production, biocatalyst formulation, process chemistry).* 'License-ready' bio-based manufacturing route for quinuclidinol that meets the needs for UK-based production (cost, foot-print, productivity, safety, sustainability).